Glaxosmithkline (GSK)

 

GSK Share PerformanceMore

52 week high1,745.5 11/10/16
52 week low1,446.5 06/12/16
52 week change -111.5 (-6.73%)
4 week volume119,645,395 30/06/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director Deals - GlaxoSmithKline PLC (GSK)

Urs Rohner, Non Executive Director, bought 567 shares in the company on the 26th July 2017 at a price of 1599.00p. The Di...

Director Deals - GlaxoSmithKline PLC (GSK)

Manvinder Banga, Non Executive Director, bought 2,267 shares in the company on the 26th July 2017 at a price of 1599.00p...

Director Deals - GlaxoSmithKline PLC (GSK)

Sir Roy Anderson, Non Executive Director, bought 567 shares in the company on the 26th July 2017 at a price of 1599.00p. T...

Director Deals - GlaxoSmithKline PLC (GSK)

Dr Vivienne Cox, Non Executive Director, bought 449 shares in the company on the 26th July 2017 at a price of 1599.00p. T...

Director Deals - GlaxoSmithKline PLC (GSK)

Sir Philip Hampton, Chairman, bought 2,736 shares in the company on the 26th July 2017 at a price of 1599.00p. The Directo...

Director/PDMR Shareholding

RNS Number: 1732M GlaxoSmithKline PLC 26 July 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Philip Hampton b) Position/status Non-Executive Chairman c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participan...

Director/PDMR Shareholding - Replacement

RNS Number: 1701M GlaxoSmithKline PLC 26 July 2017 The following amendment has been made to the Director/PDMR Shareholding announcement released on 27 April 2017 at 17:40 (BST) under RNS No 6174D in respect of the volume of notional Ordinary Shares acquired by Mr Urs Rohner (Independent Non-Executive Director) under the share allocation arran...

Half-year Report

RNS Number: 1405M GlaxoSmithKline PLC 26 July 2017 Issued: Wednesday, 26 July 2017, London U.K. GSK delivers further progress in Q2 and sets out new priorities for the Group Q2 sales of 7.3 billion, +12% AER, +3% CER Total loss per share of 3.7p, +59% AER, +29% CER; Adjusted EPS of 27.2p, +12% AER, -2% CER Financial highlights Pharmaceutical sales, 4.4...

Fundamental DataMore

P/E ratio82.207
EPS18.8
Dividend yield5.176 %

Latest discussion posts More

  • Re: New Dividend Policy

    A more positive spin fro the FT: "Emma Walmsley?s first big decision as chief executive of GlaxoSmithKline, to judge by most media reports, was selling the pharma group?s ...
    26-Jul-2017
    sound money
  • Re: The longest day ..... Day 31!!

    Games ''Keep your eyes out for those long high street queues'' And that thought is what scares a lot of investors or potential investors who keep their eyes on history, ...
    26-Jul-2017
    Phillip Reid
  • Re: New Dividend Policy

    The dividend should have been rebased 12 months ago, or before then. To allocate over 100% of FCF to the payout is complete madness as I have mentioned many times. In ...
    26-Jul-2017
    EssentialInvestor

Users' HoldingsMore

Users who hold Glaxosmithkline also hold..
BP35%
VODAFONE GRP.34%
NATIONAL GRID32%
LLOYDS GRP.32%
RDS 'B'31%

Codes & Symbols

ISINGB0009252882
SymbolsGSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK